Physician profile
David Herbstman
NPI 1841399300
$2,694.80
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $561 · 2021: $966 · 2022: $609.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.46 | 2019-2022 | |
| Abbvie INC. | $559.56 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $408.16 | 2019-2022 | |
| Janssen Biotech, INC. | $165.52 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $158.10 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $152.70 | 2019-2022 | |
| Pfizer INC. | $111.30 | 2019-2021 | |
| Daiichi Sankyo INC. | $98.98 | 2022 | |
| Vivus LLC | $95.40 | 2019-2022 | |
| Qol Medical, LLC | $90.77 | 2019-2020 | |
| Redhill Biopharma INC. | $52.06 | 2020 | |
| Ucb, INC. | $48.59 | 2019 | |
| Celgene Corporation | $26.32 | 2022 | |
| Shionogi INC | $25.77 | 2019 | |
| Gilead Sciences, INC. | $24.81 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $21.42 | 2022 | |
| Alfasigma USA, INC. | $17.69 | 2020 | |
| Evoke Pharma, INC. | $17.50 | 2021 | |
| Allergan, INC. | $17.20 | 2020 | |
| Braintree Laboratories, INC. | $15.32 | 2020 | |
| Genzyme Corporation | $12.17 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herbstman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.